Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:18 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 12,634 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period A Clear all
Active, not recruiting Phase 2 Interventional

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

NCT05418049
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Baclofen, Memantine, Roflumilast, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Nov 3, 2026, 11:18 PM EST
Completed Phase 2 Interventional Results available

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

NCT01143038
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Romiplostim
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Anaheim, California • Orange, California • Boynton Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Nov 3, 2026, 11:18 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

NCT01406938
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
AIN457 150mg, AIN457 300mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
967 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Fresno, California • Pasadena, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Nov 3, 2026, 11:18 PM EST
Terminated Phase 2 Interventional Results available

Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

NCT01658826
View directory record Official record
Conditions
Genital Herpes
Interventions
AIC316, Valacyclovir
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Indianapolis, Indiana • Portland, Oregon • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Nov 3, 2026, 11:18 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Assess AER-271

NCT03804476
View directory record Official record
Conditions
Stroke, Stroke, Acute, Stroke, Ischemic
Interventions
AER-271, Placebo
Drug
Lead sponsor
Aeromics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Nov 3, 2026, 11:18 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

NCT03353350
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
efpeglenatide (SAR439977), placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
32
States / cities
Birmingham, Alabama • Glendale, Arizona • Canoga Park, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Nov 3, 2026, 11:18 PM EST
Completed Early Phase 1 Interventional

Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

NCT02583789
View directory record Official record
Conditions
Raynaud's Phenomenon
Interventions
oral treprostinil, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Nov 3, 2026, 11:18 PM EST
Completed Phase 3 Interventional Results available

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
sparsentan, irbesartan, Dapagliflozin
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Homewood, Alabama • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 3, 2026, 11:18 PM EST
Completed Not applicable Interventional Results available

Feasibility and Acceptability of W-GenZD vs CBT-light Teletherapy for Adolescents Seeking Mental Health Services

NCT05372913
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Woebot for Adolescents (W-GenZD) Mobile Application, CBT-Lite Teletherapy Group
Device · Behavioral
Lead sponsor
Woebot Health
Industry
Eligibility
13 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Nov 3, 2026, 11:18 PM EST
Completed Not applicable Interventional

Supporting Care Partners' Well-Being With Artificial Intelligence (AI) Chatbots

NCT07145723
View directory record Official record
Conditions
Caregivers
Interventions
Earkick app
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 3, 2026, 11:18 PM EST
Completed Phase 2 Interventional Results available

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

NCT01721759
View directory record Official record
Conditions
Squamous Cell Non-small Cell Lung Cancer
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
20
States / cities
Sacramento, California • San Diego, California • Tampa, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Nov 3, 2026, 11:18 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors

NCT02938780
View directory record Official record
Conditions
Breast Cancer Female
Interventions
placebo text message, nutrition physical activity text message
Other
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
20 Years to 75 Years · Female only
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 3, 2026, 11:18 PM EST
Completed Phase 2Phase 3 Interventional Results available

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

NCT01052662
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Nov 3, 2026, 11:18 PM EST
Terminated Not applicable Interventional

The Pittsburgh Vitamin D Study: Vitamin D Supplementation in Vitamin D-deficient Subjects at Risk of Lung Cancer

NCT02532062
View directory record Official record
Conditions
Deficiency of Vitamin D3, COPD
Interventions
Cholecalciferol, multivitamin, Placebo
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Nov 3, 2026, 11:18 PM EST
Completed Phase 3 Interventional

Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR

NCT00043888
View directory record Official record
Conditions
HIV Infections
Interventions
fosamprenavir, COMBIVIR, ritonavir, TRIZIVIR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
13
States / cities
Little Rock, Arkansas • Long Beach, California • Newport Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Nov 3, 2026, 11:18 PM EST
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents

NCT00825227
View directory record Official record
Conditions
Fatigue, Chemotherapy Side Effects
Interventions
Armodafinil 150 mg/day, Placebo,
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Muscle Shoals, Alabama • Burbank, California • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Nov 3, 2026, 11:18 PM EST
Completed Not applicable Interventional

Mindfulness and Yoga Therapy for Acute Pain in Sickle Cell Disease

NCT05572294
View directory record Official record
Conditions
Sickle Cell Crisis, Sickle Cell Disease
Interventions
Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Nov 3, 2026, 11:18 PM EST
Completed Phase 3 Interventional Results available

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

NCT03746522
View directory record Official record
Conditions
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
San Diego, California • Springfield, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Nov 3, 2026, 11:18 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers

NCT01984229
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Alectinib, Posaconazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Nov 3, 2026, 11:18 PM EST
Completed Not applicable Interventional

The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors

NCT05798780
View directory record Official record
Conditions
Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer
Interventions
ENHANCE Intervention - Exercise and Nutrition, ENHANCE Intervention - Nutrition Only
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 3, 2026, 11:18 PM EST
Completed Not applicable Interventional

Know and Own Your Movement-related Metrics Via Wearable Devices

NCT05490641
View directory record Official record
Conditions
Cancer, Survivorship
Interventions
Glucose-based biofeedback, Standard feedback
Behavioral
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 3, 2026, 11:18 PM EST
Recruiting Not applicable Interventional

Improving Visual Field Deficits With Noninvasive Brain Stimulation

NCT05085210
View directory record Official record
Conditions
Visual Field Defect, Peripheral, Stroke, Visual Impairment, Hemianopsia, Quadrantanopia, Cortical Blindness, Visual Field Defect Homonymous Bilateral, Occipital Lobe Infarct, Visual Fields Hemianopsia
Interventions
transcranial random noise stimulation (tRNS), Computer Based Visual Training, Sham stimulation, Virtual Reality Based Visual Training
Device · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 3, 2026, 11:18 PM EST
Completed Not applicable Interventional

Brain and Behavior Correlates of Arm Rehabilitation

NCT04989920
View directory record Official record
Conditions
Stroke, Cardiovascular
Interventions
Experimental group: CIMT group (Constraint-Induced Movement Therapy)
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Nov 3, 2026, 11:18 PM EST
Terminated Phase 2 Interventional Results available

A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

NCT05941442
View directory record Official record
Conditions
Panic Disorder
Interventions
Darigabat, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Phoenix, Arizona • Lafayette, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 3, 2026, 11:18 PM EST